OverviewSuggest Edit

Esperion Therapeutics is a pharmaceutical company. It specializes in developing and commercializing oral, low‑density lipoprotein cholesterol (LDL-C) therapies for patients with hypercholesterolemia.

TypePublic
Founded2008
HQAnn Arbor, MI, US
Websiteesperion.com
Employee Ratings3.7
Overall CultureF

Latest Updates

Employees (est.) (Dec 2019)193(+154%)
Revenue (FY, 2020)$227.5 M(+54%)
Share Price (Mar 2021)$28.5 (+5%)
Cybersecurity ratingBMore

Key People/Management at Esperion Therapeutics

Tim Mayleben

Tim Mayleben

President, CEO
Richard Bartram

Richard Bartram

CFO
Mark Glickman

Mark Glickman

Chief Commercial Officer
Ashley Hall

Ashley Hall

Chief Development Officer
Ken Fiorelli

Ken Fiorelli

Chief Technical Operations Officer
Sheldon Koenig

Sheldon Koenig

Chief Operating Officer
Show more

Esperion Therapeutics Office Locations

Esperion Therapeutics has an office in Ann Arbor
Ann Arbor, MI, US (HQ)
3891 Ranchero Dr
Show all (1)

Esperion Therapeutics Financials and Metrics

Esperion Therapeutics Revenue

Esperion Therapeutics's revenue was reported to be $227.55 m in FY, 2020
USD

Revenue (FY, 2020)

227.5m

Net income (FY, 2020)

(143.6m)

EBIT (FY, 2020)

(121.4m)

Market capitalization (1-Mar-2021)

796.9m

Closing stock price (1-Mar-2021)

28.5

Cash (31-Dec-2020)

305.0m

EV

498.0m
Esperion Therapeutics's current market capitalization is $796.9 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

148.4m227.5m

General and administrative expense

18.3m21.4m33.1m65.9m199.6m

R&D expense

57.9m147.6m171.5m175.6m146.9m

Operating expense total

76.2m169.0m204.6m241.5m348.9m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

145.4m982.0k981.0k1.8m212.2m3.3m

General and administrative expense

5.0m5.4m5.7m6.0m7.0m9.0m12.2m13.5m18.5m41.6m47.7m

R&D expense

35.9m38.2m40.1m40.9m39.5m41.6m46.3m42.8m48.3m34.7m35.0m

Operating expense total

40.9m43.7m45.7m46.9m46.5m50.6m58.5m56.3m66.7m76.3m83.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

56.5m85.0m77.3m34.5m37.0m166.1m305.0m

Accounts Receivable

Prepaid Expenses

1.7m1.3m3.9m24.0m

Inventories

16.1m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

16.6m71.9m48.6m47.9m40.2m208.6m129.8m80.8m37.2m48.8m47.1m19.9m20.4m21.0m30.8m24.4m26.8m174.8m274.3m212.0m149.4m298.5m215.7m

Prepaid Expenses

1.3m986.0k1.8m1.3m1.1m1.6m923.0k792.0k2.8m11.4m11.5m16.9m

Inventories

1.8m8.2m9.1m

Current Assets

19.4m73.0m58.3m61.3m54.6m279.8m225.7m218.8m197.1m209.1m213.5m188.0m170.9m206.8m201.4m188.9m168.2m235.2m307.1m253.5m172.6m321.4m242.8m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(26.1m)(36.4m)(49.8m)(75.0m)(167.0m)(201.8m)(97.2m)(143.6m)

Depreciation and Amortization

70.6k160.0k236.0k252.0k258.0k265.0k547.0k

Inventories

(16.1m)

Accounts Payable

1.8m(299.0k)(1.3m)3.9m15.8m24.4m(16.1m)23.1m
USDQ2, 2013

Financial Leverage

-0.4 x
Show all financial metrics

Esperion Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Esperion Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Esperion Therapeutics Online and Social Media Presence

Embed Graph

Esperion Therapeutics Company Culture

  • Overall Culture

    F

    28/100

  • CEO Rating

    F

    18/100

  • Compensation

    F

    36/100

  • Diversity

    F

    23/100

Learn more on Comparably

Esperion Therapeutics News and Updates

Thinking about trading options or stock in Duke Energy, Esperion Therapeutics, Expedia, MSCI Inc, or Walmart?

NEW YORK, Feb. 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DUK, ESPR, EXPE, MSCI, and WMT. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Moore Kuehn Encourages Esperion Therapeutics, Inc. Investors to Contact Law Firm for Possible Claims Against Officers and Directors

NEW YORK, April 24, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating whether certain officers and directors of Esperion Therapeutics, Inc. (NASDAQ: ESPR) breached their fiduciary duties to shareholders....

Esperion Therapeutics Blogs

ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update

Fourth Quarter 2020 U.S. Product Revenue of $8.2 Million, Approximately 150 Percent Increase Compared to the Third Quarter Over 21,000 Patients on NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Tablets in the U.S. CLEAR Outcomes Study Design Highlighted in The American

ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update

ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update Content Import Mon, 11/02/2020 - 16:01 ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update Nov 2, 2020 This release is a backfill from a News Wire …

NEXLETOL® (bempedoic acid) Tablets Highlighted in EAS 2020 Presentation of Analysis Demonstrating Significant Cholesterol Lowering in People with Familial Hypercholesterolemia

- NEXLETOL® exhibited a 22% mean reduction in LDL-C levels in patients with Heterozygous Familial Hypercholesterolemia at week-12 - ANN ARBOR, Mich., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced results of pooled data from two of the company’s Phase 3 trials were

Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedoic acid) Tablets and Increase Awareness of Bad Cholesterol

Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedoic acid) Tablets and Increase Awareness of Bad Cholesterol Content Import Mon, 09/28/2020 - 16:06 Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedo…

Esperion Announces Two Data Presentations of NEXLETOL® (bempedoic acid) Tablet at the ESC Congress 2020

ANN ARBOR, Mich., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it will present a pooled analysis from four Phase 3 clinical trials of NEXLETOL ® (bempedoic acid) tablets as well as long-term safety and efficacy data from the CLEAR Harmony open-label extension study

Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update

– Highest Quarterly and First Half Total Revenue in Company History with $214 million in Total YTD Revenue – – Strong Capital Position with over $300 Million in Cash – – Extraordinary High-Quality Managed Care Coverage with Over 80% Commercial and Over 50% Medicare Part D Formulary Coverage –
Show more

Esperion Therapeutics Frequently Asked Questions

  • When was Esperion Therapeutics founded?

    Esperion Therapeutics was founded in 2008.

  • Who are Esperion Therapeutics key executives?

    Esperion Therapeutics's key executives are Tim Mayleben, Richard Bartram and Mark Glickman.

  • How many employees does Esperion Therapeutics have?

    Esperion Therapeutics has 193 employees.

  • What is Esperion Therapeutics revenue?

    Latest Esperion Therapeutics annual revenue is $227.5 m.

  • What is Esperion Therapeutics revenue per employee?

    Latest Esperion Therapeutics revenue per employee is $1.2 m.

  • Who are Esperion Therapeutics competitors?

    Competitors of Esperion Therapeutics include CSPC Pharmaceutical Group, Macleods Pharmaceuticals and Sandoz.

  • Where is Esperion Therapeutics headquarters?

    Esperion Therapeutics headquarters is located at 3891 Ranchero Dr, Ann Arbor.

  • Where are Esperion Therapeutics offices?

    Esperion Therapeutics has an office in Ann Arbor.

  • How many offices does Esperion Therapeutics have?

    Esperion Therapeutics has 1 office.